P. Furet

发表

The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis

G. Martiny-Baron, Philipp Holzer, E. Billy, 2010, Angiogenesis.

3D molecular lipophilicity potential profiles: a new tool in molecular modeling

P. Furet, A. Sele, N. Cohen, 1988 .

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

Bhabatosh Chaudhuri, Doriano Fabbro, Pascal Furet, 2002, Pharmacology & therapeutics.

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.

D. Fabbro, P. Furet, T. O'reilly, 2001, Journal of the National Cancer Institute.

Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay.

J. Mestan, D. Fabbro, W. Jahnke, 2010, Journal of the American Chemical Society.

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

F. Lombardo, D. Fabbro, W. Jahnke, 2018, Journal of medicinal chemistry.

Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking.

D. Fabbro, P. Furet, R. Portmann, 2003, Journal of medicinal chemistry.

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014, Molecular Cancer Therapeutics.

Entry into a New Class of Protein Kinase Inhibitors by Pseudo Ring Design.

P. Furet, M. Lang, T. Meyer, 2008 .

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors.

P. Furet, P. Traxler, P Furet, 1999, Pharmacology & therapeutics.

Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes

Joseph Schoepfer, Joerg Kallen, Pascal Furet, 2019, ChemMedChem.

Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53.

P. Furet, C. García-echeverría, P. Chène, 2000, Journal of medicinal chemistry.

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.

P. Furet, A. de Pover, P. Chène, 2012, Bioorganic & Medicinal Chemistry Letters.

Total synthesis and biological evaluation of the nakijiquinones.

P. Furet, A. Huwe, H. Waldmann, 2001, Journal of the American Chemical Society.

Tyrosine kinase inhibitors: From rational design to clinical trials

Pascal Furet, Guido Bold, Giorgio Caravatti, 2001, Medicinal research reviews.

Imatinib: a selective tyrosine kinase inhibitor.

D. Fabbro, P. Furet, T. Meyer, 2002, European journal of cancer.

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Daniela Gabriel, Doriano Fabbro, Pascal Furet, 2008, Molecular Cancer Therapeutics.

Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product.

P. Furet, H. Fretz, R. Soni, 2000, Biochemical and biophysical research communications.

New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck.

P. Furet, B. Pirard, S. Cowan-Jacob, 2010, Bioorganic & medicinal chemistry letters.

9‐ epi ‐Artemisinin – How a Single Stereo Center Affects Chemical Reactivity under Reductive Conditions

P. Furet, T. Allmendinger, Dorina Kotoni, 2022, Helvetica Chimica Acta.

X-ray crystallographic studies of CDK2, a basis for cyclin-dependent kinase inhibitor design in anti-cancer drug research.

P. Furet, 2003, Current medicinal chemistry. Anti-cancer agents.

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

D. Erdmann, J. Brueggen, P. Furet, 2010, Molecular Cancer Therapeutics.

A Novel Potent Oral Series of VEGFR2 Inhibitors Abrogate Tumor Growth by Inhibiting Angiogenesis.

J. Mestan, G. Martiny-Baron, C. Schnell, 2016, Journal of medicinal chemistry.

Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

W. Sellers, Angela Tam, P. Furet, 2019, Clinical Cancer Research.

Advances in Brief Prediction of Resistance to Small Molecule FLT 3 Inhibitors : Implications for Molecularly Targeted Therapy of Acute Leukemia

D. Fabbro, P. Marynen, P. Furet, 2004 .

Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.

P. Furet, P. Imbach, G. Bold, 2010, Genes & cancer.

Adaptation of the bound intrinsically disordered protein YAP to mutations at the YAP:TEAD interface.

D. Erdmann, P. Furet, P. Chène, 2018 .

Adaptation of the bound intrinsically disordered protein YAP to mutations at the YAP:TEAD interface

D. Erdmann, P. Furet, P. Chène, 2018, Protein science : a publication of the Protein Society.

A new structural class of selective and non-covalent inhibitors of the chymotrypsin-like activity of the 20S proteasome.

P. Furet, P. Imbach, M. Lang, 2001, Bioorganic & medicinal chemistry letters.

Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery.

T. Vorherr, P. Furet, A. Marzinzik, 2016, Angewandte Chemie.

Study of the cytotoxic effect of a peptidic inhibitor of the p53–hdm2 interaction in tumor cells

P. Furet, P. Chène, I. Carena, 2002, FEBS letters.

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.

J. Mestan, D. Fabbro, P. Furet, 2004, Mini reviews in medicinal chemistry.

Identification of NVP-CLR457 as an Orally Bioavailable Non-CNS-Penetrant pan-Class IA Phosphoinositol-3-Kinase Inhibitor.

C. Schnell, P. Furet, F. Blasco, 2022, Journal of medicinal chemistry.

A new class of inhibitors of secretory phospholipase A2: enolized 1,3-dioxane-4,6-dione-5-carboxamides

P. Furet, J. Pfeilschifter, S. Roggo, 1994 .

Synthesis of Modified Tripeptides and Tetrapeptides as potential bisubstrate inhibitors of the epidermal growth factor receptor protein tyrosine kinase

P. Furet, H. Mett, P. Traxler, 1997 .

Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design.

P. Furet, P. Imbach, M. Lang, 2004, Journal of medicinal chemistry.

Total Synthesis and Biological Evaluation of a C(10)/C(12)‐Phenylene‐Bridged Analog of Epothilone D

P. Furet, K. Altmann, M. Wartmann, 2004, Chemistry & biodiversity.

Substituent effects on acetylene stability. A comparison of STO-3G, 6-31G, 6-31G**, and 6-311G** calculations

P. Furet, R. Fuchs, R. Matcha, 1985 .

A new perspective on the interaction between the Vg/VGLL1-3 proteins and the TEAD transcription factors

D. Erdmann, T. Vorherr, P. Furet, 2020, Scientific Reports.

Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2.

P. Furet, C. García-echeverría, G. Caravatti, 2000, Bioorganic & medicinal chemistry letters.

Dual specificity of Src homology 2 domains for phosphotyrosine peptide ligands.

P. Furet, C. García-echeverría, P. Chène, 1997, Biochemistry.

Structure-based design of a non-peptidic antagonist of the SH2 domain of GRB2.

P. Furet, G. Caravatti, J. Rahuel, 1999, Bioorganic & medicinal chemistry letters.

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Hans Bitter, Franco Lombardo, Joseph Schoepfer, 2017, Nature.

Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching.

P. Furet, K. Altmann, F. Hofmann, 2003, Bioorganic & medicinal chemistry letters.

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.

Joerg Kallen, Pascal Furet, Keiichi Masuya, 2015, Journal of medicinal chemistry.

Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.

P. Furet, G. Bold, A. de Pover, 2014, Bioorganic & medicinal chemistry letters.

Structure-based design, synthesis, and X-ray crystallography of a high-affinity antagonist of the Grb2-SH2 domain containing an asparagine mimetic.

P. Furet, C. García-echeverría, J. Schoepfer, 1999, Journal of medicinal chemistry.

Structural basis for the high affinity of amino-aromatic SH2 phosphopeptide ligands.

P. Furet, C. García-echeverría, H. Fretz, 1998, Journal of molecular biology.

Fluoroolefin dipeptide isosteres -II.

P. Furet, T. Allmendinger, E. Hungerbühler, 1990 .

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

Doriano Fabbro, Pascal Furet, Giorgio Caravatti, 2013, Bioorganic & medicinal chemistry letters.

Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.

P. Furet, G. Caravatti, T. Zoller, 2015, Bioorganic & medicinal chemistry letters.

Identification and optimisation of 4,5-dihydrobenzo[1,2-d:3,4-d]bisthiazole and 4,5-dihydrothiazolo[4,5-h]quinazoline series of selective phosphatidylinositol-3 kinase alpha inhibitors.

C. Schnell, P. Furet, F. Blasco, 2015, Bioorganic & medicinal chemistry letters.

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.

D. Fabbro, G. Martiny-Baron, J. Brueggen, 2004, Cancer cell.

Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

P. Furet, P. Imbach, M. Lang, 2007, Bioorganic & Medicinal Chemistry Letters.

Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.

Eric Vangrevelinghe, Clive McCarthy, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.

Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

P. Furet, P. Imbach, M. Lang, 2002, Bioorganic & medicinal chemistry letters.

Verification of a designed intramolecular hydrogen bond in a drug scaffold by nuclear magnetic resonance spectroscopy.

Ariane L. Jansma, N. Gray, P. Furet, 2007, Journal of medicinal chemistry.

Ab initio studies of substituent effects on allene stability

P. Furet, R. Fuchs, R. Matcha, 1986 .

Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.

L. Meijer, P. Furet, B. Chaudhuri, 2002, Journal of medicinal chemistry.

Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411

Pascal Furet, Peter Traxler, Giorgio Caravatti, 1995, J. Comput. Aided Mol. Des..

Extended kinase profile and properties of the protein kinase inhibitor nilotinib.

J. Mestan, D. Fabbro, G. Martiny-Baron, 2010, Biochimica et biophysica acta.

New synthesis of oxcarbazepine via remote metalation of protected N-o-tolyl-anthranilamide derivatives

P. Furet, U. Beutler, W. Zaugg, 2001 .

Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.

Pascal Furet, Frédéric Stauffer, G. Rummel, 2016, ACS medicinal chemistry letters.

Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.

P. Furet, S. Maira, F. Stauffer, 2009, Future medicinal chemistry.

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.

Pascal Furet, C. Schnell, J. Brueggen, 2011, Journal of medicinal chemistry.

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.

W. Jahnke, P. Couttet, N. Ostermann, 2020, Journal of medicinal chemistry.

p53 dynamics vary between tissues and are linked with radiation sensitivity

Miles A. Miller, R. Weissleder, Y. Iwamoto, 2021, Nature Communications.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Eric Y. Durand, W. Sellers, Philipp Holzer, 2018, Cancer research.

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Hans Bitter, Joerg Kallen, Pascal Furet, 2015, eLife.

Coupling of the antennapedia third helix to a potent antagonist of the p53/hdm2 protein-protein interaction.

P. Furet, C. García-echeverría, P. Chène, 2001, Bioorganic & medicinal chemistry letters.

A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.

D. Fabbro, P. Furet, C. García-echeverría, 2000, Journal of molecular biology.

Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway.

P. Furet, C. García-echeverría, S. Maira, 2008, Bioorganic & medicinal chemistry letters.

Discovery of a novel tricyclic 4H-thiazolo[5',4':4,5]pyrano[2,3-c]pyridine-2-amino scaffold and its application in a PI3Kα inhibitor with high PI3K isoform selectivity and potent cellular activity.

P. Furet, C. Fritsch, R. Mah, 2015, Bioorganic & medicinal chemistry letters.

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

Wolfgang Jahnke, Doriano Fabbro, Pascal Furet, 2010, Biochimica et biophysica acta.

Small Molecule Therapeutics Characterization of the Novel and Speci fi c PI 3 K a Inhibitor NVP-BYL 719 and Development of the Patient Strati fi cation Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014 .

Effect of Potent and Selective Inhibitors of the Grb2 SH2 Domain on Cell Motility*

D. Fabbro, P. Furet, G. Caravatti, 1999, The Journal of Biological Chemistry.

Potent, Selective, and Orally Bioavailable Inhibitors of VPS34 Provide Chemical Tools to Modulate Autophagy in Vivo.

P. Finan, M. Glick, P. Furet, 2016, ACS medicinal chemistry letters.

Medicinal chemistry efforts towards the identification and development of inhibitors of phosphatidylinositol 3-kinases (PI3Ks) and related protein kinases for cancer treatment

Philipp Holzer, P. Furet, C. García-echeverría, 2007 .

Structural basis for specificity of GRB2-SH2 revealed by a novel ligand binding mode

D. Erdmann, P. Furet, C. García-echeverría, 1996, Nature Structural Biology.

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

Gad Getz, Ignaty Leshchiner, Dejan Juric, 2017, Cancer discovery.

Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. CANCER

G. Getz, A. Iafrate, P. Furet, 2022 .

Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA).

D. Fabbro, P. Furet, J. Bain, 2003, The Biochemical journal.

The Angiotensin II AT2 Receptor Subtype

S. Whitebread, P. Furet, M. Gasparo, 1994 .

Prediction of Resistance to Small Molecule FLT3 Inhibitors

Doriano Fabbro, Peter Marynen, Pascal Furet, 2004, Cancer Research.

A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.

Joseph Schoepfer, Clive McCarthy, Pascal Furet, 2011, Cancer research.

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

Doriano Fabbro, Pascal Furet, D. Fabbro, 2006, Acta crystallographica. Section D, Biological crystallography.

Targeted Therapy with Imatinib: An Exception or a Rule?

J. Mestan, D. Fabbro, P. Furet, 2005 .

Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.

Pascal Furet, Guido Bold, Arghya Ray, 2008, Blood.

Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis.

J. Mestan, C. Schnell, J. Wood, 2004, Biochimica et biophysica acta.

Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

P. Furet, C. Leblanc, Christine C Genick, 2017, MedChemComm.

Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases.

J. Mestan, P. Furet, T. Meyer, 2004, Bioorganic & medicinal chemistry letters.

FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

W. Sellers, P. Couttet, P. Furet, 2019, Molecular Cancer Therapeutics.

A new perspective on the evolution of the interaction between the Vg/VGLL1-3 proteins and the TEAD transcription factors

D. Erdmann, T. Vorherr, P. Furet, 2020, bioRxiv.

The TEAD4–YAP/TAZ Protein–Protein Interaction: Expected Similarities and Unexpected Differences

D. Erdmann, P. Furet, F. Hofmann, 2013, Chembiochem : a European journal of chemical biology.

Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue

Joseph Schoepfer, Pascal Furet, R. Schmitz, 2009, BMC Chemical Biology.

Comparison of the Kinase Profile of Midostaurin (Rydapt) with That of Its Predominant Metabolites and the Potential Relevance of Some Newly Identified Targets to Leukemia Therapy.

P. Furet, P. Manley, G. Caravatti, 2018, Biochemistry.

Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents.

Pascal Furet, Guido Bold, P. Furet, 2006, Journal of medicinal chemistry.

2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4.

P. Furet, C. Leblanc, M. Wartmann, 2018, ACS medicinal chemistry letters.

Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.

J. Mestan, C. Schnell, J. Wood, 2002, Journal of medicinal chemistry.

Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy

D. Erdmann, P. Furet, P. Chène, 2019, The FEBS journal.

Entry into a new class of protein kinase inhibitors by pseudo ring design.

P. Furet, M. Lang, T. Meyer, 2008, Bioorganic & medicinal chemistry letters.

Towards a rational approach in the finding of potent peptide ligands for Grb2 SH2

P. Furet, C. García-echeverría, H. Fretz, 2002 .

Structure-based design of peptidomimetic ligands of the Grb2-SH2 domain.

P. Furet, C. García-echeverría, H. Fretz, 1998, Bioorganic & medicinal chemistry letters.

Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes*

M. Geiser, P. Furet, A. Goepfert, 2009, Journal of Biological Chemistry.

Modulation of the SH2 Binding Specificity and Kinase Activity of Src by Tyrosine Phosphorylation within Its SH2 Domain (*)

P. Furet, N. Lydon, D. Stover, 1996, The Journal of Biological Chemistry.

Design of two new chemotypes for inhibiting the Janus kinase 2 by scaffold morphing.

P. Furet, M. Gerspacher, Carole Pissot-Soldermann, 2010, Bioorganic & medicinal chemistry letters.

The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase.

M. Zvelebil, M. Dowsett, P. Furet, 2009, Cancer research.

The Vascular Endothelial Growth Factor Receptor Inhibitor PTK 787 / ZK 222584 Inhibits Aromatase

M. Zvelebil, M. Dowsett, P. Furet, 2009 .

ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia

W. Sellers, F. Lombardo, W. Jahnke, 2014 .

STI571: A New Treatment Modality for CML?

P. Furet, E. Buchdunger, J. Zimmermann, 2001 .

Abstract 4738: Cellular resistance screening with a novel selective c-Met inhibitor reveals a spectrum of missense mutations that partially overlap with activating mutations found in cancer patients

J. Monahan, Michael D. Jones, P. Furet, 2011 .

Discovery of a novel class of highly potent inhibitors of the p53-MDM2 interaction by structure-based design starting from a conformational argument.

Philipp Holzer, P. Furet, P. Chène, 2016, Bioorganic & medicinal chemistry letters.

Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension.

P. Furet, I. Konstantinova, A. Saunders, 2016, Journal of medicinal chemistry.

Discovery of a new class of catalytic topoisomerase II inhibitors targeting the ATP-binding site by structure based design. Part I.

P. Furet, P. Chène, J. Schoepfer, 2009, Bioorganic & medicinal chemistry letters.

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.

Eric Vangrevelinghe, Marc Lang, Pascal Furet, 2010, Bioorganic & medicinal chemistry letters.

The First Class of Small Molecules Potently Disrupting the YAP‐TEAD Interaction by Direct Competition

P. Furet, P. Chène, T. Schmelzle, 2022, ChemMedChem.

Leveraging Advanced In Silico Techniques in Early Drug Discovery: A Study of Potent Small-Molecule YAP-TEAD PPI Disruptors

Callum J. Dickson, V. Hornak, P. Furet, 2023, J. Chem. Inf. Model..

The AT 2 Receptor: Historical Perspective

S. Whitebread, P. Furet, M. Gasparo, 2015 .

The AT2 Receptor

S. Whitebread, P. Furet, M. Gasparo, 2015 .

Structure-based design and synthesis of high affinity tripeptide ligands of the Grb2-SH2 domain.

P. Furet, C. García-echeverría, H. Fretz, 1998, Journal of medicinal chemistry.

Prospects for Antiangiogenic Therapies Based upon VEGF Inhibition

P. Furet, P. Manley, 2001 .

Structure-based design of potent CDK1 inhibitors derived from olomoucine

Thomas Meyer, Hans-Georg Capraro, Pascal Furet, 2000, J. Comput. Aided Mol. Des..

Abstract LB319: IAG933, a selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations

P. Furet, F. Hofmann, Laurent Sansregret, 2023, Cancer Research.

Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP‐TEAD Protein‐Protein Interaction Inhibitors

P. Furet, P. Chène, T. Schmelzle, 2023, ChemMedChem.

In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor.

Philipp Holzer, P. Furet, S. Ferretti, 2018, Bioorganic & medicinal chemistry letters.

Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways.

P. Furet, C. García-echeverría, H. Fretz, 2000, Current pharmaceutical design.

Modeling of the binding mode of a non-covalent inhibitor of the 20S proteasome. Application to structure-based analogue design.

P. Furet, P. Imbach, M. Lang, 2001, Bioorganic & medicinal chemistry letters.

Structure-based design of potent linear peptide inhibitors of the YAP-TEAD protein-protein interaction derived from the YAP omega-loop sequence.

P. Furet, P. Chène, T. Schmelzle, 2019, Bioorganic & medicinal chemistry letters.

Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching

Thomas Meyer, Pascal Furet, Peer R. E. Mittl, 2001, J. Comput. Aided Mol. Des..

Corrigendum to “Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation” [Bioorg. Med. Chem. Lett. 23 (2013) 3741–3748]

D. Fabbro, J. Hamon, P. Furet, 2013 .

Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor.

P. Furet, G. Bold, T. Meyer, 2004, European journal of medicinal chemistry.

Biological Crystallography Structural Biology Contributions to the Discovery of Drugs to Treat Chronic Myelogenous Leukaemia

D. Fabbro, G. Rummel, P. Furet, 2022 .

Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 1.

P. Furet, C. García-echeverría, H. Fretz, 2000, Bioorganic & medicinal chemistry letters.

Mapping the X+1 binding site of the Grb2-SH2 domain with α,α-disubstituted cyclic α-amino acids

P. Furet, C. García-echeverría, J. Rahuel, 1999 .

CGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridylmethyl)phthalazines as inhibitors of VEGF- and BFGF-induced angiogenesis

J. Mestan, G. Martiny-Baron, J. Wood, 2002 .

Potent antagonists of the SH2 domain of Grb2: optimization of the X+1 position of 3-amino-Z-Tyr(PO3H2)-X+1-Asn-NH2.

P. Furet, C. García-echeverría, H. Fretz, 1998, Journal of medicinal chemistry.

Discovery of 3-aminobenzyloxycarbonyl as an N-terminal group conferring high affinity to the minimal phosphopeptide sequence recognized by the Grb2-SH2 domain.

P. Furet, C. García-echeverría, H. Fretz, 1997, Journal of medicinal chemistry.

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

W. Sellers, Philipp Holzer, P. Furet, 2015, eLife.

Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.

E. Jacoby, Philipp Holzer, P. Furet, 2015, Bioorganic & medicinal chemistry letters.

Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds.

P. Furet, P. Furet, M. Lang, 1993, Journal of medicinal chemistry.

Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.

C. Schnell, P. Furet, S. Jeay, 2016, Bioorganic & medicinal chemistry letters.

Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction.

Nathan Brown, Edgar Jacoby, Caroline Engeloch, 2009, Methods in molecular biology.

Tyrosine kinase inhibitors: From rational design to clinical trials

J. Wood, P. Furet, P. Traxler, 2001, Medicinal research reviews.

4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.

P. Furet, N. Lydon, P. Traxler, 1996, Journal of medicinal chemistry.

Identification of FAM181A and FAM181B as new interactors with the TEAD transcription factors

D. Erdmann, P. Furet, P. Chène, 2019, Protein science : a publication of the Protein Society.

Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes.

D. Curtis, Christopher J. Wilson, P. Furet, 2023, Journal of Medicinal Chemistry.

4-Amidinoindan-1-one 2'-amidinohydrazone: a new potent and selective inhibitor of S-Adenosylmethionine decarboxylase.

P. Furet, H. Mett, P. Furet, 1993, Journal of medicinal chemistry.

Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

P. Furet, C. Leblanc, Christine C Genick, 2017, MedChemComm.

Pyrrolo[2,3-d]pyrimidine and Pyrazolo[3,4-d]pyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase

P. Furet, R. Cozens, N. Lydon, 2001 .

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

J. Mestan, D. Fabbro, W. Jahnke, 2010, Biochimica et biophysica acta.

2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors.

P. Furet, P. Imbach, H. Mett, 1999, Bioorganic & medicinal chemistry letters.

Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes

Philipp Holzer, P. Furet, P. Chène, 2019, ChemMedChem.

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201.

Eric Y. Durand, W. Sellers, Philipp Holzer, 2018, Cancer research.

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction.

P. Furet, A. de Pover, P. Chène, 2012, Bioorganic & medicinal chemistry letters.

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

P. Furet, F. Hofmann, S. Brachmann, 2024, Nature cancer.

New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis

Stover, Roth, J. Mestan, 2000, Journal of medicinal chemistry.

S-adenosylmethionine decarboxylase inhibitors: new aryl and heteroaryl analogues of methylglyoxal bis(guanylhydrazone).

P. Furet, H. Mett, P. Furet, 1993, Journal of medicinal chemistry.

TEAD4 (216-434);Y429F COMPLEXED WITH YAP PEPTIDE (60-100) AND MYRISTOATE (COVALENTLY BOUND) AT 2.05A (P41212 CRYSTAL FORM); MYRISTOYLATION WAS DONE BY ADDING MYR-COA

D. Erdmann, P. Furet, P. Chène, 2018 .

Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.

P. Furet, N. Lydon, P. Traxler, 1997, Journal of medicinal chemistry.

Author Correction: Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.

P. Furet, F. Hofmann, S. Brachmann, 2024, Nature cancer.

Dissecting the Interaction Fingerprints and Binding Affinity of BYL719 Analogs Targeting PI3Kα.

P. Furet, Sepehr Dehghani-Ghahnaviyeh, Cihan Soylu, 2024, The journal of physical chemistry. B.

Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors.

P. Furet, S. Cowan-Jacob, C. Scheufler, 2016, Bioorganic & medicinal chemistry letters.

Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2.

D. Fabbro, P. Furet, T. Meyer, 1995, European journal of biochemistry.